. . . . . . . . . . . . . . . . . . . . . . "Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge."@en . . "6\u03B1-Methyl-17-acetoxy progesterone"@en . . . "* 64110 +/- 42662 mL/min [postmenopausal women under fasting conditions with a single Dose of 2 \u00D7 10 mg] * 74123 +/- 35126 mL/min [postmenopausal women under fasting conditions with a single Dose of 8 \u00D7 2.5 mg] * 41963 +/- 38402 mL/min [postmenopausal women following daily administration of one PROVERA 10 mg tablet for 7 days]"@en . . . . . . . . . . . . . . . . . . . . "17-Acetoxy-6\u03B1-methylprogesterone"@en . . . . . . . . . . . . "Methylacetoxyprogesterone"@en . . . . . . . . . . . "6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate"@en . . . . . "Humans and other mammals"@en . . . . . . . "Take with food."@en . "6alpha-Methyl-17-acetoxy progesterone"@en . . . "Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens."@en . . . . "approved"@en . . . . "6\u03B1-Methyl-17\u03B1-hydroxyprogesterone acetate"@en . "Medroxyprogesterone 17-acetate"@en . "6-alpha-Methyl-17-alpha-acetoxyprogesterone"@en . . . . . "Metigestrona"@en . . " "@en . "Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17\u03B1-hydroxy-6\u03B1-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. [Wikipedia]"@en . . . . . . . . . . . "Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders."@en . . . . "6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate"@en . . . . . "Medroxyacetate progesterone"@en . . . . . "17alpha-Hydroxy-6alpha-methylprogesterone acetate"@en . "17-Acetoxy-6alpha-methylprogesterone"@en . . . "90%"@en . . . "Klaus ANNEN, Thomas Linz, Karl-Heinz Neff, Rolf Bohlmann, Henry Laurent, \"PROCESS FOR PREPARING 17ALPHA-ACETOXY-6-METHYLENEPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE AND MEGESTROL ACETATE.\" U.S. Patent US20090012321, issued January 08, 2009."@en . "(6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione"@en . "Medroxyprogesterone acetate"@en . . . . . . . "Rapidly absorbed from GI tract"@en . "Medroxyprogesterone Acetate"@en . "17\u03B1-hydroxy-6\u03B1-methylprogesterone acetate"@en . "71-58-9"@en . "# Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH: Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1-2):171-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19434889 # Lenco W, Mcknight M, Macdonald AS: Effects of cortisone acetate, methylprednisolone and medroxyprogesterone on wound contracture and epithelization in rabbits. Ann Surg. 1975 Jan;181(1):67-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1119869"@en . "6alpha-Methyl-17alpha-hydroxyprogesterone acetate"@en . "50 days"@en . . . . . . . . . . . "investigational"@en . . . . . . . . . "MPA"@en . . . . "Following oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates."@en . . .